Participated · Equity · Nov 2025

Skeletalis is developing next-generation therapeutics aimed at musculoskeletal disorders, with an initial focus on osteoporosis. Its lead small-molecule candidate employs a proprietary bone-targeting technology that delivers disease-modulating therapy directly to skeletal tissue, minimizing systemic exposure. By re-engineering drug engagement with bone targets, the company seeks to improve tolerability, extend therapeutic durability, and ultimately prevent fractures while preserving bone mineral density. The approach is designed to avoid the safety liabilities associated with current osteoporosis drugs. Skeletalis is led by founder and CEO Ben Swanson, DDS, PhD, working alongside Dr. Colin Greineder. The recently secured financing will fund advancement of the osteoporosis candidate through pre-clinical and early clinical development. No operating metrics such as revenue or user count have been disclosed.

Participated · Equity · Oct 2025

Faeth Therapeutics, headquartered in Austin, Texas, is advancing multi-node therapies that block cancer growth signals while controlling tumor fuel supply. Its proprietary, AI-driven MetabOS platform uncovers metabolic dependencies in tumors and other diseases, guiding the development of therapeutic and nutritional interventions. The company’s lead program is a Phase 2 study in endometrial cancer that is expected to deliver a full data readout in Q3 2026. Additional plans include a Phase 1 trial in locally advanced rectal cancer using a non-essential amino acid-restricted regimen and an investigational program for Hereditary Tyrosinemia Type 1, the first application of MetabOS beyond oncology. Founded in 2019 by noted scientists Lewis Cantley, Siddhartha Mukherjee, Karen Vousden, Scott Lowe, and Greg Hannon, the company is led by CEO Anand Parikh. To date, Faeth has raised $92 million in capital to fund its pipeline and expand the MetabOS platform.

Participated · Equity · May 2025

Arkestro operates a Predictive Procurement Platform that combines AI, behavioral science, and game theory with its patented Negotiation Science, Supplier Science, and Process Science. The platform accelerates procurement cycles, enhances supplier collaboration, and drives an average of 18.8% cost savings on every $1M of spend. Trusted by Fortune 500 manufacturers, energy companies, and global supply chain organizations, Arkestro helps procurement teams influence significantly more spend and become a proactive, results-driven function. The company has been recognized in Gartner’s 2024 Hype Cycle and as a Top Tech – Sourcing provider in Fall 2024 SolutionMap. Arkestro plans to expand its capabilities and bring predictive procurement transformation to more enterprises, with emphasis on the energy and broader industrial markets. The company recently secured new capital to accelerate its AI-powered procurement innovation and global growth. Arkestro offers a self-negotiating procurement platform that simulates procurement processes, suggests pricing and commercial terms, and automates reaching agreements with suppliers. The system combines machine learning, game theory and behavioral science to identify optimal suppliers from a global network and maintain service and supply levels. It serves manufacturing and non-manufacturing customers alike and counts Box as a customer. The company launched in 2017 (originally as BidOps), has around 50 employees, and is aggressively hiring while building a geographically diverse and remote-capable team. Arkestro maintains a major engineering hub in Atlanta and prioritizes diversity and inclusive hiring as it expands the startup and product. Led by Founder and CEO Edmund Zagorin, Bid Ops provides a cloud-based procurement automation platform that automates vendor negotiations for enterprise and public procurement teams using AI. The system creates a target price for each line item that accounts for value-based assessments of a vendor’s qualifications and likely performance on the contract. Procurement executives can use these forecasts to compare and contrast bids and obtain competitive pricing and stronger commercial relationships with growth-oriented vendor partners. The company raised $1.75M in seed funding to support its operations. Bid Ops intends to use the proceeds to continue to expand operations. The platform focuses on improving procurement outcomes through AI-driven price targets and bid comparison tools.

Led · Seed · Apr 2025

PHNX Materials has developed a process to strip sulfur and aluminum from coal fly ash pulled from landfills so the ash can be used as a cement substitute in concrete mixes. By prepping low‑quality ash, PHNX aims to unlock a larger supply of fly ash for concrete makers, who can use up to 30% ash to replace cement and lower carbon intensity. The company plans to sell cleaned ash to concrete producers and recover sulfur, aluminum and other compounds for sale to relevant industries; it is also exploring extraction of rare earth elements. PHNX’s approach targets material saved in the roughly 843 fly ash landfills in the U.S. and responds to shrinking ash availability after coal plant closures reduced coal’s share of U.S. electricity from 51% to 15%. The startup frames its work as a scalable way to decarbonize concrete production, noting that each ton of cement produced in the U.S. emits about 0.8 tons of CO2.

Participated · Series B · Mar 2025

Character Biosciences integrates genomics, longitudinal clinical datasets, and AI-driven modeling to pinpoint disease drivers and create precision therapeutics for progressive polygenic disorders, beginning with ophthalmology. Its pipeline is led by CTX114, a complement inhibitor for geographic atrophy, and CTX203, a lipid modulator intended to halt progression to advanced AMD. The company is also advancing programs for primary open-angle glaucoma, seeking to address large unmet medical needs in vision care. Recent leadership hires—including a new CMO, Chief Data & Analytics Officer, Head of Clinical Network and Longitudinal Research, and Head of People—strengthen its clinical and data capabilities. Character Bio positions its unique patient data platform as a competitive advantage to improve drug-development success rates. Financially, the firm has secured more than $110 million in Series B funding, providing capital to move its first therapeutic programs toward the clinic.